Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of first-line (1L) nivolumab (N) plus ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
    Meeting Abstract

    Borghaei, H.; Balli, D.; Paz-Ares, L.; Reck, M.; Ramalingam, S. S.; Brahmer, J. R.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Gainor, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies
    Meeting Abstract

    Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 trial of KT‐333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors
    Meeting Abstract

    Smith, S.; Olszewski, A.; Starodub, A. N.; Stevens, D. A.; Feldman, T.; Porcu, P.; Epstein-Peterson, Z.; Huen, A.; Pinter‐Brown, L.; Mattour, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save